Edmund Sears is a Respiratory physician affiliated with Maine Medical Center. OpenAlex indexes 36 publications with 324 citations (h-index 9).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
100 Foden Rd
West Building, Suite 103
South Portland, ME 041062327
Telephone
207-828-1122Provider last certified this registry record 1 Apr 2025.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ICU Medical IncProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
65.6%Corticosteroid26.5%Breo Ellipta36%Trelegy Ellipta24%Budesonide-Formoterol Fumarate13%Symbicort10%Arnuity Ellipta9%Dulera8%Part D<11 patientsbeta2-Adrenergic Agonist14.9%Albuterol Sulfate Hfa89%Ventolin Hfa11%Part D<11 patients+ 3 more classes in this area
Metabolism & gastrointestinal
22.1%Corticosteroid11.8%Prednisone100%Part D≥38 patientsProton pump inhibitor5.6%Omeprazole65%Pantoprazole Sodium35%Part D<11 patients+ 1 more class in this area
Anti-infectives
8.1%Macrolide Antimicrobial4.2%Azithromycin100%Part D<11 patientsShort-acting sulfonamides3.9%Sulfamethoxazole-Trimethoprim100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Impact of COVID‐19 and CFTR Modulators on Cystic Fibrosis: A Real‐World Analysis of Care Patterns
Pediatric Pulmonology
2026 - 754 Comprehensiveness of cystic fibrosis care: Comparing outcomes across telehealth, in-person, and hybrid visit models
Journal of Cystic Fibrosis
2025 - 759 Long-term impact of elexacaftor/tezacaftor/ivacaftor on healthcare utilization in cystic fibrosis
Journal of Cystic Fibrosis
2025 - 757 The impacts of highly effective modulator therapy and telehealth on cystic fibrosis care: Changes in visit frequency
Journal of Cystic Fibrosis
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Meic Schmidt, MD
Maine Medical Center
Arjang Djamali, MD
Maine Medical Center
Cornelius McGinn, MD
Maine Medical Center
Jeremy Morton, MD
Maine Medical Center
Fernando Martinez, MD
University of Massachusetts Chan Medical School
David Gozal, MD
Ronald Crystal, MD
Weill Cornell Medicine
Bartolome Celli, MD
Brigham and Women's Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”